• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by I-MAB (Amendment)

    2/13/24 11:26:50 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMAB alert in real time by email
    SC 13G/A 1 sch13ga.htm
    Page 1 of 5
    CUSIP No. 44975P 103
    SCHEDULE 13G/A

     

     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     

     
    SCHEDULE 13G
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 4) *
     

     
    I-MAB
    (Name of Issuer)
     
    Ordinary shares, par value US$0.0001 per share
    (Title of Class of Securities)
     
    44975P 103 **
    (CUSIP Number)
     
    December 31, 2023
    (Date of the Event Which Requires Filing of this Statement)
     


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed :
     
    ☐ Rule 13d-1(b)
    ☒ Rule 13d-1(c)
    ☐ Rule 13d-1(d)
     
    *
    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    **
    There is no CUSIP number assigned to the ordinary shares. CUSIP number 44975P 103 has been assigned to the American Depositary Shares (“ADSs”) of the Issuer, each ten (10) ADSs representing twenty three (23) ordinary shares, which are quoted on the Nasdaq Global Market under the symbol “IMAB.”
     
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provision of the Act (however, see the Notes.)
     
     

    Page 2 of 5
    CUSIP No. 44975P 103
    SCHEDULE 13G/A
                 
      1.    
     
    NAME OF REPORTING PERSONS.
     
    GIC Private Limited
      2.
     
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
    (a)  ☐        (b)  ☐
     
      3.
     
    SEC USE ONLY
     
      4.
     
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Republic of Singapore
           
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
      
    5.    
      
    SOLE VOTING POWER
     
    4
      
    6.
      
    SHARED VOTING POWER
     
    0
      
    7.
      
    SOLE DISPOSITIVE POWER
     
    4
      
    8.
      
    SHARED DISPOSITIVE POWER
     
    0
                 
      9.    
     
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    4
    10.
     
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES   ☐
    (See Instructions)
    11.
     
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0.0% (1)
    12.
     
    TYPE OF REPORTING PERSON (See Instructions)
     
    CO
     

    (1)
    Based on 190,033,689 ordinary shares of the Issuer outstanding as of June 30, 2023, as disclosed in the Form 6-K filed by the Issuer with the Securities and Exchange Commission on August 17, 2023.
     

    Page 3 of 5
    CUSIP No. 44975P 103
    SCHEDULE 13G/A

    Item 1(a)
    Name of Issuer
     
    I-MAB (the “Issuer”)

    Item 1(b)
    Address of Issuer’s Principal Executive Offices
     
    55th Floor, New Bund Center, 555 West Haiyang Road, Pudong District
    Shanghai, 200124
     
    People’s Republic of China
     
    Item 2(a)
    Name of Persons Filing
     
    GIC Private Limited (“GIC”)
     
    Item 2(b)
    Address of Principal Business Office or, if none, Residence
     
    168 Robinson Road
    #37-01 Capital Tower
    Singapore 068912
     
    Item 2(c)
    Citizenship
     
    Republic of Singapore
     
    Item 2(d)
    Title of Class of Securities
     
    Ordinary shares, par value US$0.0001 per share (the “Ordinary Shares”)
     
    Item 2(e)
    CUSIP Number
     
    There is no CUSIP number assigned to the ordinary shares. CUSIP number 44975P 103 has been assigned to the American Depositary Shares (“ADSs”) of the Issuer, each ten (10) ADSs representing twenty three (23) ordinary shares, which are quoted on the Nasdaq Global Market under the symbol “IMAB.” 
     
    Item 3
    If this statement is filed pursuant to §§240.13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
     
    Not applicable.
     
    Item 4
    Ownership

    (a - c)  The aggregate number of securities and percentage of the class of securities of the Issuer beneficially owned by the Reporting Person named in Item 2(a), as well as the number of securities as to which such person is deemed to have sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, shared power to dispose or direct the disposition, is set forth in the following tables:
     
    Reporting Person
    No. of Securities Beneficially Owned
    Percent of Class
    Voting Power
    Dispositive Power
       
    (3)
    Sole (1), (2)
    Shared (1), (2)
    Sole (1), (2)
    Shared (1), (2)
    GIC Private Limited
    4
    0.0%
    4
    0
    4
    0
     

    (1)
    GIC is a fund manager and only has 2 clients – the Government of Singapore (“GoS”) and the Monetary Authority of Singapore (“MAS”).  Under the investment management agreement with GoS, GIC has been given the sole discretion to exercise the voting rights attached to, and the disposition of, any shares managed on behalf of GoS. As such, GIC has the sole power to vote and power to dispose of 4 shares beneficially owned by it.


    Page 4 of 5
    CUSIP No. 44975P 103
    SCHEDULE 13G/A

    GIC is wholly-owned by the GoS and was set up with the sole purpose of managing Singapore’s foreign reserves. The GoS disclaims beneficial ownership of such shares.


    (2)
    GIC disclaims membership in a group.


    (3)
    Based on 190,033,689 ordinary shares of the Issuer outstanding as of June 30, 2023, as disclosed in the Form 6-K filed by the Issuer with the Securities and Exchange Commission on August 17, 2023.
     

    Item 5
    Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owners of more than five percent of the class of securities, check the following ☒

    Item 6
    Ownership of More than Five Percent on Behalf of Another Person
     
    Not applicable.

    Item 7
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company
     
    Not applicable.

    Item 8
    Identification and Classification of Members of the Group
     
    Not applicable.

    Item 9
    Notice of Dissolution of Group
     
    Not applicable.

    Item 10
    Certifications
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
     


    Page 5 of 5
    CUSIP No. 44975P 103
    SCHEDULE 13G/A


     
    SIGNATURE
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct as dated.
     
    GIC PRIVATE LIMITED




    By: /s/ Diane Liang Weishan
    Name: Diane Liang Weishan
    Title: Senior Vice President
    Date: February 13, 2024





    By: /s/ Toh Tze Meng
    Name: Toh Tze Meng
    Title: Senior Vice President
    Date: February 13, 2024
     
    Get the next $IMAB alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IMAB

    DatePrice TargetRatingAnalyst
    12/9/2021$96.00Buy
    Siebert Williams Shank
    11/1/2021$83.00 → $85.00Buy
    Needham
    9/1/2021$75.00 → $95.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $IMAB
    SEC Filings

    View All

    SEC Form 6-K filed by I-MAB

    6-K - I-Mab (0001778016) (Filer)

    8/20/25 7:00:03 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by I-MAB

    6-K - I-Mab (0001778016) (Filer)

    8/11/25 7:06:07 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by I-MAB

    424B5 - I-Mab (0001778016) (Filer)

    8/4/25 7:30:26 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Siebert Williams Shank initiated coverage on I-Mab with a new price target

    Siebert Williams Shank initiated coverage of I-Mab with a rating of Buy and set a new price target of $96.00

    12/9/21 8:33:47 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Needham reiterated coverage on I-MAB with a new price target

    Needham reiterated coverage of I-MAB with a rating of Buy and set a new price target of $85.00 from $83.00 previously

    11/1/21 4:39:06 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on I-MAB with a new price target

    HC Wainwright & Co. reiterated coverage of I-MAB with a rating of Buy and set a new price target of $95.00 from $75.00 previously

    9/1/21 6:14:32 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMAB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    I-Mab Reports Second Quarter 2025 Financial Results and Provides Business Update

    Positive givastomig Phase 1b dose escalation data in combination with immunochemotherapy in patients with 1L gastric cancers presented at ESMO GI 2025 showing 83% ORR at doses selected for ongoing expansion studyTopline data from planned dose expansion study of givastomig expected in Q1 2026Strengthened balance sheet with net proceeds of approximately $61.2 million from August 2025 underwritten offering; pro-forma cash balance of approximately $226.8 million as of June 30, 2025, after giving effect to the offering; expected to fund planned operating expenses and capital expenditures through the fourth quarter of 2028 ROCKVILLE, Md., Aug. 20, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (I

    8/20/25 7:00:00 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    I-Mab Completes Enrollment in Planned Phase 1b Dose Expansion Study for Givastomig in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers

    Enrollment in the planned second dose expansion cohort completed ahead of expectationsTopline results expected in Q1 2026 Positive Phase 1b dose escalation data presented at ESMO GI on July 2nd ROCKVILLE, Md., Aug. 11, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that enrollment in the planned Phase 1b dose expansion cohorts evaluating givastomig, a bispecific Claudin 18.2 x 4-1BB antibody, in combination with nivolumab and mFOLFOX6, has been completed ahead of expectations. The Phase 1b study (NCT04900818) is evaluating the

    8/11/25 7:00:00 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Everest Medicines Expands Strategic Investment in I-MAB

    - Everest will invest US$30.9 million (equivalent to approximately HK$242.6 million) in cash in I-Mab. Inclusive of I-MAB shares already held by Everest, the pro forma ownership will be 16.1%. - I-Mab's Claudin 18.2 x 4-1BB bispecific antibody, givastomig, demonstrated an impressive overall response rate (ORR) of 83% in combination with immunotherapy in a Phase 1b trial of first line gastric cancers. - I-Mab's differentiated 4-1BB receptor targeting platform and bispecific antibody pipeline are highly complementary with the Company's existing mRNA cancer vaccines and in vivo CAR-T platform. - Complementary and synergistic clinical development and business development platforms, especially I-

    8/1/25 8:56:00 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMAB
    Leadership Updates

    Live Leadership Updates

    View All

    I-Mab Reports Full Year 2024 Financial Results and Provides Business Update

    Continued positive momentum in givastomig Phase 1b combination trial in first-line gastric cancer, with topline dose escalation data (n=17) expected in 2H 2025Enrollment completed ahead of schedule in the first givastomig Phase 1b dose expansion cohort; momentum continues in the second expansion cohortStrong financial position supported by $173.4 million of cash and cash equivalents, and short-term investments as of December 31, 2024; provides runway into 2027, through expected clinical readouts for givastomig ROCKVILLE, Md., April 03, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology

    4/3/25 4:01:00 PM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program

    Givastomig: a Claudin 18.2 ("CLDN18.2") x 4-1BB bispecific antibody, will be the lead clinical program following the Company's portfolio prioritizationThe Company has completed enrollment of a dose escalation study of givastomig in combination with nivolumab plus chemotherapy, and data is expected in the early second half of 2025; a 40-patient dose expansion study is now underway with data expected in early 2026Cash balance of $184.4 million (as of September 30, 2024), expected to support operations into 2027, complemented by a strengthened U.S.-based leadership team and streamlined operating modelROCKVILLE, MD, Jan. 6, 2025 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based,

    1/6/25 7:00:00 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    I-Mab Reports Third Quarter 2024 Results

    Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy dataOn track to dose first patient in randomized Phase 2 study of uliledlimab in first-line mNSCLC in 1H 2025Appointed Dr. Sean Fu as permanent CEO effective November 1, 2024Estimated cash runway into 2027, based on $184.4 million in cash and cash equivalents, and short-term investments as of September 30, 2024ROCKVILLE, Md., Nov. 14, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced financial results for the three and nine months ended

    11/14/24 7:00:00 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMAB
    Financials

    Live finance-specific insights

    View All

    I-Mab to Release Q3 2024 Financial Results on November 14, 2024

    ROCKVILLE, Md., Oct. 31, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to release financial results for the third quarter ended September 30, 2024, on Thursday, November 14, 2024, pre-market Eastern Time. The Company will not host a conference call to discuss its third quarter 2024 financial results. The Company intends to host an investor update call in conjunction with its 2024 full-year fin

    10/31/24 7:00:00 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates

    Completed divestiture of China operationsUliledlimab IND clearance paves the way for U.S. combination studies in first-line mNSCLC (CD73 antibody)Clinical collaboration and supply agreement with Bristol Myers Squibb strengthens givastomig first-line gastric cancer combination studies (CLDN18.2 X 4-1BB bispecific)Ragistomig presentation at ASCO 2024 highlights encouraging early data (PD-L1 X 4-1BB bispecific)Well-positioned for pipeline advancement with $207.5 million in cash and cash equivalents, and short-term investments as of June 30, 2024, and cash runway expected into 2027I-Mab will hold a conference call and webcast today, August 28th, at 8:00 AM ETROCKVILLE, Md., Aug. 28, 2024 /PRNews

    8/28/24 7:00:00 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    I-Mab to Release 1H 2024 Financial Results on August 28, 2024

    Conference call to discuss financial results and recent business highlights to take place on Wednesday, August 28, 2024, at 8:00 AM ET ROCKVILLE, Md., Aug. 14, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to host a conference call and webcast on Wednesday, August 28, 2024, 8:00 AM ET to discuss financial results, pipeline progress and recent business highlights for the half year ended June 30, 2024.

    8/14/24 7:00:00 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by I-MAB (Amendment)

    SC 13G/A - I-Mab (0001778016) (Subject)

    2/13/24 11:26:50 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by I-MAB (Amendment)

    SC 13G/A - I-Mab (0001778016) (Subject)

    2/9/24 4:01:20 PM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by I-MAB

    SC 13D - I-Mab (0001778016) (Subject)

    12/1/23 2:41:06 PM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care